KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

被引:5
作者
Lee, Sung-Hun [1 ]
Yang, Min-Kyu [1 ]
Lim, Jong-Hyun [1 ]
Seo, Ho-Won [2 ]
Yi, Kyu-Yang [2 ]
Yoo, Sung-eun [2 ]
Lee, Byung-Ho [2 ]
Won, Hyung-Sik [3 ]
Lee, Chang-Soo [1 ]
Choi, Wahn-Soo [4 ]
Shin, Hwa-Sup [1 ]
机构
[1] Konkuk Univ, Coll Biomed & Hlth Sci, Dept Appl Biochem, Div Life Sci, Chungju 380701, Chungbuk, South Korea
[2] Korea Res Inst Chem Technol, Div Med Sci, Taejon 305343, South Korea
[3] Konkuk Univ, Coll Biomed & Hlth Sci, Dept Biotechnol, Div Life Sci, Chungju Chungbuk 380701, South Korea
[4] Konkuk Univ, Coll Med, Chungju 380701, South Korea
关键词
KR-31762; cardioprotection; K-ATP; ischemia; reperfusion; rat heart;
D O I
10.1007/s12272-001-1182-9
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cardioprotective effects of KR-31762, a newly synthesized K-ATP(+) opener, were evaluated in rat models of ischemia/reperfusion (I/R) heart injury. In isolated rat hearts subjected to 30-min global ischemia followed by 30-min reperfusion, KR-31762 (3 and 10 mu M) significantly increased the left ventricular developed pressure (LVDP) and double product (heart rate x LVDP) after 30-min referfusion in a concentration-dependent manner, while decreasing the left ventricular end-diastolic pressure (LVEDP). KR-31762 also significantly increased the time to contracture (TTC) during ischemic period (20.0, 22.4 and 26.4 min for control, 3 and 10 mu M, respectively), while decreasing the release of lactate dehydrogenase (LDH) from the heart during 30 min reperfusion (30.4, 14.3 and 19.7 U/g heart weight, respectively). All these parameters except LDH release were reversed by glyburide (1 mu M), a nonselective blocker of K-ATP(+) channel, but not by 5-hydroxydecanoate, a selective blocker of mitoK(ATP)(+) channel. In anesthetized rats subjected to 45-min occlusion of left anterior descending coronary artery followed by 90-min reperfusion, KR-31762 significantly decreased the infarct size (60.8, 40.5 and 37.8% for control, 0.3 and 1.0 mg/kg, iv, respectively). KR-31762 slightly relaxed the isolated rat aorta precontracted with methoxamine (IC50: 23.5 mu M). These results suggest that KR-31762 exerts potent cardioprotective effects through the opening of sarcolemmal K-ATP channel in rat hearts with the minimal vasorelaxant effects.
引用
收藏
页码:482 / 489
页数:8
相关论文
共 28 条
[1]   POTASSIUM CHANNELS AND PRECONDITIONING OF ISOLATED RABBIT CARDIOMYOCYTES - EFFECTS OF GLYBURIDE AND PINACIDIL [J].
ARMSTRONG, SC ;
LIU, GS ;
DOWNEY, JM ;
GANOTE, CE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1995, 27 (08) :1765-1774
[3]   Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress [J].
Coghlan, MJ ;
Carroll, WA ;
Gopalakrishnan, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (11) :1627-1653
[4]   ATP-REGULATED K+ CHANNELS PROTECT THE MYOCARDIUM AGAINST ISCHEMIA REPERFUSION DAMAGE [J].
COLE, WC ;
MCPHERSON, CD ;
SONTAG, D .
CIRCULATION RESEARCH, 1991, 69 (03) :571-581
[5]   M-LDH serves as a sarcolemmal KATP channel subunit essential for cell protection against ischemia [J].
Crawford, RM ;
Budas, GR ;
Jovanovic, S ;
Ranki, HJ ;
Wilson, TJ ;
Davies, AM ;
Jovanovic, A .
EMBO JOURNAL, 2002, 21 (15) :3936-3948
[6]   Hemodynamic and cardiac effects of BMS-180448, a novel K(+)ATP opener, in anesthetized dogs and isolated rat hearts [J].
DAlonzo, AJ ;
Grover, GJ ;
Darbenzio, RB ;
Sewter, JC ;
Hess, TA ;
Dzwonczyk, S ;
Sleph, PG .
PHARMACOLOGY, 1996, 52 (02) :101-112
[7]   Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers.: 6.: Effect of modifications at C6 of benzopyranyl cyanoguanidines [J].
Ding, CZ ;
Rovnyak, GC ;
Misra, RN ;
Grover, GJ ;
Miller, AV ;
Ahmed, SZ ;
Kelly, Y ;
Normandin, DE ;
Sleph, PG ;
Atwal, KS .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (18) :3711-3717
[8]   Evidence for mitochondrial KATP channels as effectors of human myocardial preconditioning [J].
Ghosh, S ;
Standen, NB ;
Galiñanes, M .
CARDIOVASCULAR RESEARCH, 2000, 45 (04) :934-940
[9]  
Gomoll AW, 1997, J PHARMACOL EXP THER, V281, P24
[10]  
Grover GJ, 2001, J PHARMACOL EXP THER, V297, P1184